Journal
DRUG RESISTANCE UPDATES
Volume 11, Issue 6, Pages 210-218Publisher
CHURCHILL LIVINGSTONE
DOI: 10.1016/j.drup.2008.09.002
Keywords
Notch; Gamma-secretase inhibitor (GSI); Hematological malignancies; T-ALL; Multiple myeloma; B-cell malignancies
Categories
Funding
- NCI NIH HHS [R01 CA130923-01A1, R01 CA130923] Funding Source: Medline
Ask authors/readers for more resources
Activation of Notch signaling has been implicated in pathogenesis of various hematologic tumors including leukemias, lymphomas, and multiple myeloma. Pre-clinical studies have suggested that inhibition of Notch could be an attractive new approach to treatment of hematologic malignancies. This review discusses most recent findings in the field and potential role of Notch signaling as a therapeutic target focusing on the effects of gamma-secretase inhibitors. (C) 2008 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
